These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10695041)

  • 1. [Mechanisms for the therapeutic effect of herpes polyvaccines in chronic ophthalmic herpes and genital herpes].
    Barinskiĭ IF; Karpovich LG; Gubanova EI; Belkina IV; Semenova TB; Lazarenko AA; Davydova AA; Samoĭlenko II; Kasparov AA
    Vopr Virusol; 2000; 45(1):30-3. PubMed ID: 10695041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seventeen years of application of herpes vaccines in Bulgaria.
    Dundarov S; Andonov P
    Acta Virol; 1994 Aug; 38(4):205-8. PubMed ID: 7879710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indices of the immune status of recurrent herpes patients being treated with a herpes polyvaccine].
    Belokrinitskiĭ DV; Karpovich LG; Barinskiĭ IF; Bukovskaia SN; Semenova TB
    Vopr Virusol; 1987; 32(2):229-33. PubMed ID: 3037800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indices of lymphocyte functional activity in patients with recurrent cutaneous-genital herpes during treatment with a herpes vaccine].
    Karpovich LG; Blokha VV; Kalashnikova TV; Bychkova AA; Semenova TB
    Vopr Virusol; 1986; 31(2):200-5. PubMed ID: 3014750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HSV-1 herpes vaccination by LUPIDON H: preliminary results.
    De Maria A; Tundo P; Romano A; Grima P
    Adv Exp Med Biol; 1995; 371B():1599-600. PubMed ID: 7502864
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunity to ocular and genital herpes simplex viruses infections.
    Chentoufi AA; BenMohamed L; Van De Perre P; Ashkar AA
    Clin Dev Immunol; 2012; 2012():732546. PubMed ID: 23326289
    [No Abstract]   [Full Text] [Related]  

  • 7. Control of herpes simplex virus infections of the genital tract by vaccination.
    Buchan A; Skinner GR; Fuller A; Hartley C; Hallworth J; Stocker D; Melling J; Wiblin C
    Vaccine; 1985 Mar; 3(1):49-53. PubMed ID: 4002836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Herpetic pathology and current methods of treating herpetic lesions].
    Zhdanov VM; Barinskiĭ IF; Galegov GA; Ershov FI
    Sov Med; 1983; (10):65-9. PubMed ID: 6362030
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dynamics of cellular immunity indices in patients with ophthalmic herpes treated with a herpetic polyvaccine].
    Barinskiĭ IF; Blokha VV; Bukovskaia SN; Belokrinitskiĭ DV; Belkina IV
    Vopr Virusol; 1988; 33(2):212-7. PubMed ID: 2842963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment trials of the therapeutic efficacy of the drug "Zovirax" in some recurrent ocular and genital herpetic infections.
    Muţiu A; Sahnazarov N; Crişan I
    Rom J Virol; 1998; 49(1-4):27-42. PubMed ID: 10892424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a therapeutic vaccine for HSV-2.
    Hosken NA
    Vaccine; 2005 Mar; 23(17-18):2395-8. PubMed ID: 15755634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.
    Milligan GN; Dudley-McClain KL; Chu CF; Young CG
    Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpetic eye disease: immunopathogenesis and therapeutic measures.
    Deshpande S; Banerjee K; Biswas PS; Rouse BT
    Expert Rev Mol Med; 2004 Mar; 6(8):1-14. PubMed ID: 15061872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific immunostimulation in the therapy of recurrent herpes simplex type I or II].
    Veneroni G; Calixte C; Bozzo Costa E; Germogli R
    Boll Ist Sieroter Milan; 1987; 66(6):427-34. PubMed ID: 2839208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action of inactivated herpes vaccine in rabbits with chronic herpetic infections].
    Barinskiĭ IF; Zaĭtseva NS; Krichevskaia EI; Slepova OS; Vinogradova VI
    Vopr Virusol; 1977; (6):670-5. PubMed ID: 602145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of cytostatics on the course and outcomes of experimental herpes infection in rabbits].
    Kolomiets AG; Gasich EL; Duboĭskaia GP; Chekina AIu; Moroz AG; Barinskiĭ IF; Votiakov VI
    Biull Eksp Biol Med; 1993 Feb; 115(2):173-5. PubMed ID: 8043799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of a suppository form of the interferon inducer poludan and potentiation of its action by hyaluronic acid].
    Barinskiĭ IF; Alimbarova LM; Samoĭlenko II; Gubanova EI; Kosiakova NP; Fadeeva LL; Petracheva ON; Semenova TB; Kasparov AA
    Vopr Virusol; 1999; 44(5):237-9. PubMed ID: 10544454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Specific immunotherapy of recurrent genital herpes].
    Grebeniuk VN
    Vestn Dermatol Venerol; 1983 Nov; (11):12-4. PubMed ID: 6322468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.